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The adipose tissue is an active endocrine organ that releases a
wide array of substances, globally termed adipokines. Among these,
visfatin is a multifaceted molecule, structurally identical to the
extracellular form of nicotinamide phosphoribosyltransferase
(Nampt), which enzymatically converts nicotinamide into nicotina-
mide mononucleotide (NMN) and whose circulating levels are
enhanced in metabolic disorders (reviewed in [1]).
Obesity, the metabolic syndrome and type 2 diabetes are being
increasingly recognized as causative of premature vascular aging even
though the underlying mechanisms are only starting to be elucidated
[2,3]. Vascular aging, which is currently regarded as a cardiovascular
risk factor, is characterized by a series of morphological and functional
alterations including endothelial dysfunction, arterial stiffness, calci-
ﬁcation and cell senescence [4]. Evidence that adipokines could play a
role in the development of these underlying phenomena is limited.
Here, we explored whether visfatin/Nampt plays a role in promoting
premature human endothelial cell senescence. The study was
approved by the ethics committee of Universidad Autónoma de
Madrid and Hospital Universitario de Getafe.
Treatment of cultured human umbilical vein endothelial cells
(HUVEC) with visfatin/Nampt increased the fraction of cells
staining positive for senescence-associated-β-galactosidase (SA-β-
gal), a marker of cell senescence [5], in a concentration-dependent
manner, with 50 ng/ml being the lowest concentration tested that
caused a signiﬁcant effect (Fig. 1A and B). The pro-senescence
effect of visfatin/Nampt (50 ng/ml) was time-dependent, and
similar in its extent to that induced by exogenously added H2O2
(50 μmol/l), with over 60% of the cells becoming SA-β-gal+ after
96 h exposure in both cases (data not shown). These results raised
the possibility that visfatin/Nampt might induce senescence by
causing oxidative stress. Indeed, visfatin/Nampt stimulated NADPH
oxidase activity (Fig. 1C), a major source of reactive oxygen species
in endothelial cells, as determined by lucigenin-derived chemilu-
minescence [6]. Furthermore, the NADPH oxidase inhibitor apoc-
ynin (30 μmol/l) prevented the increase in SA-β-gal+ cells elicited
by visfatin/Nampt (Fig. 1D). These results demonstrate that NADPH
oxidase activation mediates the induction of human endothelial
cell senescence by visfatin/Nampt.
Premature senescence often results from oxidative stress causing
extensive DNA damage, particularly at telomeres [7]. Hence, to
dissect further the mechanism involved in visfatin/Nampt-induced
senescence, we looked for the appearance of phosphorylated histone
H2AX (γH2AX) foci, which are formed at sites of DNA damage and
dysfunctional telomeres [8]. Immunoﬂuorescence microscopy
revealed that visfatin/Nampt caused a concentration-dependent
increase in γH2AX foci, which were found scattered over the total
nuclear DNA as well as co-localizing with telomeric TRF-1 signals in
the so called telomere dysfunction-induced foci (TIFs) [9] (Fig. 2A
and B). This effect was qualitatively similar to that seen when cells
were treated with etoposide (20 μmol/l), a topoisomerase inhibitor
known to cause extensive DNA damage (Fig. 2A). Furthermore,
Western blot analysis revealed that after treatment with visfatin/
Nampt, HUVEC exhibited higher p53 levels (Fig. 2D), in line with the
concept that stabilization of this protein is a key downstream signaling
event mediating the response to DNA damage and telomere dysfunction
[10].
Different actions of visfatin/Nampt in the cardiovascular system
have been reported to rely on Nampt enzymatic activity [1]. In
agreement with this premise FK866 (10 μmol/l), a highly speciﬁc
Nampt inhibitor [11], blunted all the observed effects of visfatin/
Nampt, namely the activation of NADPH oxidase (Fig. 1C), the
increase in SA-β-gal+ cells (Fig. 1E), the increase in γH2AX foci and
in cells positive for TIFs (Fig. 2C), and the rise of p53 levels
(Fig. 2D). The involvement of Nampt activity was further sub-
stantiated by the fact that the product of its enzymatic reaction,
NMN (100 μmol/l), raised NADPH oxidase activity (Fig. 1C),
increased the number of SA-β-gal+ cells (Fig. 1E), promoted the
formation of γH2AX foci and TIFs (Fig. 2C), and enhanced cellular
p53 levels (Fig. 2D), all to an extent similar to that seen in cells
treated with visfatin/Nampt.
In conclusion, this work demonstrates that visfatin/Nampt pro-
motes premature endothelial cell senescence by a mechanism that
relays on its Nampt activity and on the activation of NADPH oxidase,
and that ultimately results in the induction of DNA damage, telomere
dysfunction and p53 up-regulation. These ﬁndings suggest that
through its pro-senescence properties, visfatin/Namptmay contribute
to vascular aging and its associated pathologies in the context of
metabolic diseases.
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Fig. 1. Visfatin induces endothelial cell senescence via NADPH oxidase activation. HUVEC cultured as previously described [6] were treated for 24 h with the following compounds:
50 ng/ml visfatin (VF), 10 μmol/l FK866, 100 μmol/l NMN, and/or 30 μmol/l apocynin, or with various concentrations of VF as indicated. Senescent cells were detected by SA-β-gal
staining [5]. The fraction of SA-β-gal positive (blue) cells was determined by manual scoring at least 800 cells in each sample under an inverted microscope. NADPH oxidase activity
was measured in cell lysates by lucigenin-derived chemiluminescence [6]. (A) Phase contrast photomicrographs showing SA-β-gal staining and (B) Concentration-response for the
effect of visfatin (ﬁlled symbols) vs vehicle (empty symbols) on the accumulation of SA-β-gal positive cells. Results are expressed as a percentage of the total number of cells in the
ﬁelds of view; n = 5–7. (C) NADPH oxidase activity (n= 4) and (D, E) SA-β gal positive cells after the indicated treatments (n = 3–7). Results (mean ± SEM) are expressed relative to
the values measured in untreated cultures; n denotes the number of independent experiments performed. ⁎P b 0.05, ⁎⁎P b 0.01 and ⁎⁎⁎P b 0.001 by one- or two-way analysis of variance
(ANOVA) as appropriate, followed by Bonferroni's post hoc tests.
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Fig. 2. Visfatin promotes DNA damage and telomere dysfunction. (A–C) Cultures were treated as described in Fig. 1 and then DNA damage foci and telomere dysfunction induced foci
(TIFs) were detected by immunoﬂuorescence microscopy as previously described [8] using antibodies against γH2AX (red) and TRF-1 (green). Cells were counterstainedwith DAPI
(blue). (A) Representative deconvolved images of HUVEC treatedwith either 50 ng/ml visfatin or 20 μmol/l etoposide. Arrows in themerged images point to sites of colocalization. The right-
most small panels showenlarged views of the boxed areas in themerged images. Bar = 15 μm. (B)Dose–response for the effect of visfatin on the formation ofγH2AX foci and TIFs expressed as
meanﬂuorescentvoxels/cell andaspercentageof cellswith≥ 5TIFs/cell, respectivelyand (C)quantiﬁcationofγH2AX foci andTIFsafter the indicated treatments.Data represent the averageof3
experimentswith N200 cells scored in each case. (D)Western blot analysis of p53 protein expression 18 after treatment, calculated as the ratio of the intensity of the p53 band to the intensity of
the corresponding actin bands. Results (mean± SEM) are expressed relative to the values measured in untreated cells. n= 3–6. ⁎P b 0.05, ⁎⁎P b 0.01 and ⁎⁎⁎P b 0.001 by one way ANOVA,
followed by Bonferroni's post hoc tests.
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